We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Darktrace Plc | LSE:DARK | London | Ordinary Share | GB00BNYK8G86 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 576.80 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
25/7/2023 08:00 | 400p is proving a tough nut to crack. Could pop if it can conclusively take out this resistance | crosswires | |
25/7/2023 07:43 | Indeed as usual mostly nonsense posted on these boards 😂 For the short term positivity rules since the E&Y report and decent TU. Mid Sept earnings next time something concrete will drive the shares | crosswires | |
25/7/2023 07:35 | With those insider sales? | plunger2 | |
24/7/2023 14:17 | Takeover coming? | stealive | |
20/7/2023 09:50 | And there you go as the big boys are given some space to build positions in DARK on the journey back to £10+ | apotheki | |
20/7/2023 08:24 | Not really what I was saying p2 as buy backs by a company are a totally different issue to investors buying shares. Buy backs smooth out the market in more rocky times and that is all they should be used for in my view. | apotheki | |
20/7/2023 08:20 | Exactly. Should we buy at a price that the company won't? What a run. Not complaining! | plunger2 | |
20/7/2023 08:13 | Or they are with the input of their brokers playing a very smart game in that now does the share price really require DARK to be buying shares every day when so many others including the big boys want to buy in?!?!? | apotheki | |
20/7/2023 08:05 | Or there is a price limit? | apotheki | |
20/7/2023 07:47 | No transaction in own shares. Program finished? | crosswires | |
20/7/2023 07:21 | There it is! | thomstar | |
19/7/2023 21:51 | Price target increased by 8.1% to UK£4.59Up from UK£4.24, the current price target is an average from 15 analysts.New target price is 18% above last closing price of UK£3.90.Stock is up 5.8% over the past year.The company is forecast to post a net loss per share of US$0.021 compared to earnings per share of US$0.0023 last year. | r9505571 | |
19/7/2023 15:50 | 393.60 ✔️ | crosswires | |
19/7/2023 15:39 | Strong finish, should see 4 tomorrow | thomstar | |
19/7/2023 10:05 | Wall Street back open at 2.30 pm our time | apotheki | |
19/7/2023 10:00 | The yanks love stocks such as DARK | apotheki | |
19/7/2023 09:59 | Like a coiled spring, more looking to buy than sell, afternoon could see a spike | crosswires | |
19/7/2023 07:08 | Yes then 500p | apotheki | |
19/7/2023 07:07 | Bteak 4 quid today and we are away | thomstar | |
18/7/2023 20:31 | The consensus outlook for fiscal year 2023 has been updated.2023 losses forecast to reduce from -US$0.031 to -US$0.022 per share.Revenue forecast steady at US$544.2m.Software industry in the United Kingdom expected to see average net income growth of 4.1% next year.Consensus price target of UK£4.24 unchanged from last update.Share price rose 30% to UK£3.72 over the past week. | r9505571 | |
18/7/2023 15:59 | 9 million pound buy. This is followed by an 88 thousand buy. Hope nobody is short tomorrow | stealive | |
18/7/2023 15:55 | An interesting UT - 2364888 @ 375.70. Good start tomorrow. | aberloon2 | |
18/7/2023 13:23 | One of Caulkwells better tips ,,, most have done badly … incl CAPITA..and N BROWN .. | gripfit | |
18/7/2023 13:15 | Darktrace plc issued a trading update for its fourth quarter and full FY23 ended 30th June 2023 this morning. The Group expects FY2023 revenue growth of at least 31% to $544.3 million and 29.2% in constant currency for Annualised Recurring Revenue to $626.5 million. The Group added 396 net new customers in the fourth quarter, for a total of 1,362 in the financial year, bringing its customer base at 30th June 2023 to 8,799, up 18.3% year-over-year. The Group’s preliminary view is that adjusted EBITDA margin for the year should be no less than 22.0%. FY24 guidance is for ARR up to $635.5 million with an adjusted EBITDA margin for FY 2024 of around 22%. On a separate note E&Y has concluded its review and the Group’s previously published financial statements will not be impacted. Valuation remains the main cloud for the investment case, forward PE ratio is still over 33x with PS ratio at 5.6x, both are bottom quartile for the Software & IT Services market. Share price has spiked 23% today on the successful completion of the E&Y review, but otherwise has been drifting sideways through 2023 and lacks positive momentum. Monitor for now... ...from WealthOracle | km18 | |
18/7/2023 12:30 | I would imagine this will take out £4 this week. Splendid | crosswires |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions